Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.

It's a great honor to have completed the present study and a pleasure to see it published.

In this study, we aimed to investigate the metabolomic, lipid, and lipoprotein early changes induced by bariatric surgery and antiobesity/antidiabetic drugs (i.e., GLP-1 RA) in patients with obesity and/or T2D; to explore the potential shared or distinct changes observed in the metabolome, the impact of weight loss as a potential confounder and whether the different types of bariatric surgery, (i.e., vertical sleeve gastrectomy and Roux-en-Y gastric bypass), may cause different effects on the metabolome.

Highlights

  • Bariatric surgery had a more pronounced effect on weight loss, metabolomic and lipidomic changes compared to liraglutide treatment at four and twelve weeks postoperatively.

  • Early metabolomic and lipidomic differences between bariatric surgery and liraglutide are attributed mainly to weight loss.

  • Acetoacetate, β-hydroxybutyrate, and citrate changes may reflect reduced calorie intake and diet-driven metabolomic and lipidomic alterations postoperatively.

  • Roux-en-Y gastric bypass and sleeve gastrectomy exhibit similar effects on metabolomic, lipid, and lipoprotein parameters.

This study promotes future research: on identifying surrogate markers to predict the effectiveness and cardiometabolic outcomes of these interventions; whether the beneficial cardiometabolic effects are weight-loss dependent or independent; providing an insight into the molecular implications of the different therapeutic approaches (i.e., pharmacological vs. surgical) allowing a more personalized approach and improving the health outcomes and healthcare management in patients with obesity and/or type 2 diabetes.

Read the full article here.

Previous
Previous

Member of the Editorial Board of the JCEM (Journal of Clinical Endocrinology & Metabolism)

Next
Next

Circulating levels of five proglucagon-derived peptides in response to intravenous or oral glucose or lipids and to a mixed-meal in subjects with normal weight, overweight, and obesity